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Estrone Sulfate Transport and
Steroid Sulfatase Activity in
Colorectal Cancer: Implications for
Hormone Replacement Therapy
Lorna C. Gilligan1, Ali Gondal1, Vivien Tang1, Maryam T. Hussain1, Anastasia Arvaniti1,
Anne-Marie Hewitt1 and Paul A. Foster1,2*
1 Institute of Metabolism and Systems Research, Centre for Endocrinology, Diabetes, and Metabolism, University of
Birmingham, Birmingham, UK, 2 Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners,
Birmingham, UK
Hormone replacement therapy (HRT) affects the incidence and potential progression
of colorectal cancer (CRC). As HRT primarily consists of estrone sulfate (E1S),
understanding whether this conjugated estrogen is transported and metabolized in
CRC will define its potential effect in this malignancy. Here, we show that a panel of
CRC cell lines (Colo205, Caco2, HCT116, HT-29) have steroid sulfatase (STS) activity,
and thus can hydrolyze E1S. STS activity is significantly higher in CRC cell lysate,
suggesting the importance of E1S transport in intracellular STS substrate availability.
As E1S transport is regulated by the expression pattern of certain solute carrier organic
anion transporter polypeptides, we show that in CRC OATP4A1 is the most abundantly
expressed transporter. All four CRC cell lines rapidly transported E1S into cells, with this
effect significantly inhibited by the competitive OATP inhibitor BSP. Transient knockdown
of OATP4A1 significantly disrupted E1S uptake. Examination of estrogen receptor status
showed ERα was present in Colo205 and Caco2 cells. None of the cells expressed ERβ.
Intriguingly, HCT116 and HT29 cells strongly expressed the G protein coupled estrogen
receptor (GPER), and that stimulation of this receptor with estradiol (E2) and G1, a
GPER agonist, significantly (p < 0.01) increased STS activity. Furthermore, tamoxifen
and fulvestrant, known GPER agonist, also increased CRC STS activity, with this effect
inhibited by the GPER antagonist G15. These results suggest that CRC can take up
and hydrolyze E1S, and that subsequent GPER stimulation increases STS activity in
a potentially novel positive feedback loop. As elevated STS expression is associated
with poor prognosis in CRC, these results suggest HRT, tamoxifen and fulvestrant may
negatively impact CRC patient outcomes.
Keywords: estrogen, colorectal cancer, steroid sulfatase, OATP, SLCO, GPER, tamoxifen
Abbreviations: BPS, bromsulphthalein; CRC, colorectal cancer; E1, estrone; E2, estradiol; E1S, estrone sulfate; ER, estrogen
receptor; FBS, fetal bovine serum; GPER, G-protein coupled estrogen receptor; HRT, hormone replacement therapy; OATP,
organic anion transporter polypeptides; sFBS, charcoal-stripped fetal bovine serum; SLCO, solute carrier organic transporter
family; STS, steroid sulfatase; SULT, sulfotransferase.
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INTRODUCTION
Estrogens play an important role in the etiology of CRC (Foster,
2013). Pre-menopausal women are protected against CRC
compared to age-matched men (Farquhar et al., 2005), and data
from the Women’s Health Initiative suggests post-menopausal
women on HRT, a combination of estrone sulfate (E1S) and
progestins, have a 40% reduced incidence of developing CRC
compared to women not on HRT (Chlebowski et al., 2004).
Despite this epidemiological evidence suggesting HRT as
protective against CRC, evidence also exists showing estrogens
influence CRC proliferation. For example, the CRC cell line
Lovo increases proliferation, via a FASN-mediated mechanism,
when exposed to estradiol (E2) (Santolla et al., 2012). Indeed,
E2 increases the proliferation of the CRC cell line Caco2
(Di Domenico et al., 1996) and T84 (Hennessy et al., 2005), and
inhibits apoptosis in DLD-1 cells (Messa et al., 2005). CRC
patients on HRT present at a later and more advanced stage
of disease (Chlebowski et al., 2004), suggesting estrogens as
mitogenic in CRC. Thus, the ability of CRC to take up and
consequently metabolize E1S will define local concentrations of
active estrogens and subsequent action.
Steroid sulfatase is the key enzyme involved in hydrolyzing
E1S to E1 (Figure 1) (Mueller et al., 2015), and its
activity is known to directly increase the proliferation of
estrogen-dependent breast cancer (Foster et al., 2006) and
endometrial cancer (Foster et al., 2008b). Inhibition of STS has
shown significant promise against ERα positive breast cancer
(Stanway et al., 2006; Foster et al., 2008a). Intriguingly, STS
expression, elevated E1 and E2 intratumoural concentrations, are
associated with a poor prognosis in CRC patients (Sato et al.,
2009). This suggests that colonic estrogen metabolism may play
an important role in CRC patient outcomes.
However, very little is known about whether E1S is transported
into CRC. Sulfated steroids require transport into cells via solute
carrier organic anion transporting polypeptides (SLCO/OATP);
membrane bound proteins that transport a plethora of organic
anions (Roth et al., 2012). Six different SLCO/OATP (OATP1A2,
OATP1B1, OATP1B3, OATP2B1, OATP3A1, OATP4A1) are
known to effectively transport E1S (Mueller et al., 2015),
although their expression and action in CRC is poorly defined.
Other OATPs are known to transport E1S (OATP4C1 and
OATP1C1), however OATP4C1 is primarily expressed in the
kidney (Mikkaichi et al., 2004), and microarray analysis shows
it may have some expression in the liver but not the human
colon (Bleasby et al., 2006). OATP1C1 is localized to human
brain and testis (Pizzagalli et al., 2002), and is not evident in
human colorectal tissue, as measure by microarray (Bleasby et al.,
2006).
Here, we investigate STS activity and E1S transport kinetics
in four CRC cell lines. We demonstrate that OATP4A1 is most
likely the principle E1S transporter in CRC and that all cell lines
have the ability to hydrolyze E1S. We also show that STS activity
in CRC may be regulated by local E2 availability via a novel GPER
mechanism.
MATERIALS AND METHODS
Compounds
STX64 (Irosustat, 667COUMATE) was kindly supplied by
Prof. Barry Potter (University of Oxford, UK). G1 and G15
were purchased from Torcis Bioscience (Abingdon, UK). E2,
tamoxifen, fulvestrant, and BSP were purchased from Sigma-
Aldrich (Dorset, UK).
Cell Culture
The CRC cell lines Colo205, HCT116, and HT29 were purchased
from the American Type Culture Collection, USA; Caco2 and
JEG3 cells were purchased from The European Collection
of Cell Cultures (ECACC). Prior to experiments, all cell
lines were authenticated by short tandem repeat profiling
and were used between passages 10 and 35. Furthermore, all
experiments were performed during the exponential growth
phase of the cell line. HCT116 and HT29 were routinely cultured
in McCoy’s 5a modified medium (Gibco, Life Technologies,
USA) with 10% v/v heat inactivated FBS (Sigma-Aldrich,
UK). Colo205 cells were culture in RPMI with 10% FBS;
Caco2 cells were cultured in MEM with 10% FBS. JEG3
cells were cultured in DM-F12 (Gibco, USA) with 10%
FBS. All culture mediums were supplemented with 2 mM
L-glutamine (Sigma-Aldrich, UK) and 1% PenStrep (Gibco,
USA). JEG3 cells were used as control as they exhibit high STS
activity.
FIGURE 1 | Steroid sulfatase activity in CRC cell lines. E1S is transported across the cell membrane by OATPs and once intracellular E1S can be hydrolyzed by
STS to form E1.
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For experimental conditions, cells were initially starved of
estrogens for 72 h by placing them in their appropriate phenol-
red free medium plus 10% charcoal stripped FBS (sFBS) (Sigma-
Aldrich, UK). After starvation, HCT116 and HT29 cells were
treated with E2 (100 nM), G1 (100 nM), G15 (1 µM), Tamoxifen
(10 nM) or fulvestrant (1 µM) in stripped medium for 24 h prior
to measuring STS activity.
STS Activity Assay
In vitro STS activities of cell lines were measured as previously
described (Purohit et al., 1997). Briefly, in intact cell assays,
cells were incubated with appropriate medium containing
[6,7-3H] E1S (4 × 105 dpm, Perkin-ElmerLS, Boston, MA, USA)
adjusted to a final concentration of 20 µM with unlabeled E1S
(Sigma-Aldrich, UK). [4-14C] E1 (1 × 104 dpm, Perkin-Elmer)
was also included in the reaction mixture to monitor procedural
losses. Samples were incubated for 18 h at 37◦C after which the
product, E1, was separated from E1S by partition with toluene.
A toluene aliquot was removed and 3H and 14C radioactivity
measured by liquid scintillation spectrometry. The mass of
E1S hydrolyzed was calculated from the 3H counts detected
corrected for procedural losses. A protein measurement was
obtained for the cells by lysing the cells with RIPA buffer
(Sigma-Aldrich, UK) followed by a BCA assay (Thermo Fisher
Scientific, UK).
To determine STS activity in cell lysates, cells were first
lysed with RIPA buffer and protein content determined using
a BCA assay. Subsequently, 100 µg of cell protein was
incubated for 4 h with PBS containing [6,7-3H] E1S (4 × 105
dpm) adjusted to a final concentration of 20 µM with
unlabeled E1S. [4-14C] E1 (1 × 104 dpm) was again used
to monitor procedural losses. E1 was separated from E1S by
partition with toluene and 3H and 14C radioactivity measured
by liquid scintillation spectrometry. Results for both intact
and cell lysates were determined as pmol E1 formed/h/mg
protein.
qRT-PCR Analysis
From cells mRNA was purified from T75 flasks or six well
plates at approximately 80% confluency using RNeasy kits
(QIAGEN, Crawley, UK) and stored at −80◦C. Aliquots
containing 5 µg of mRNA were reverse transcribed in a
final volume of 20 µl to form cDNA using Tetro cDNA
Synthesis Kit (Bioline Reagents, Ltd, UK). RT-PCR reactions
were performed in a ‘Rotor Gene 2000 Real-Time Cycler’
(Corbett Life Science, Cambridge, UK) with 1 µl cDNA
in a final volume of 12 µl, using Taqman universal PCR
master mix and Taqman expression assays containing primers
and probes for OATP1A2, OATP1B1, OATP1B3, OATP2B1,
OATP3A1, OATP4A1, and for the endogenous control gene,
RPLP0 (Applied Biosystems, UK). In CRC, RPLPO is considered
the most reliable single standard gene to examine (Sørby et al.,
2010). The conditions were as follows: 95◦C for 10 min;
followed by 40 cycles of 95◦C for 15 s, and 60◦C for 60 s.
Relative mRNA expression was calculated using the comparative
quantisation algorithm in the Rotor Gene 6 software (Corbett Life
Science).
E1S Uptake Studies
Cells were seeded at 200,000 cells per well in 6-well plates and
allowed to acclimatize for 24 h. Appropriate phenol red free
medium containing 10% sFBS plus [6,7-3H] E1S (4 × 105 dpm)
was placed on the cells and was subsequently removed after 2, 5,
10, 15, 20, 30 min. For OATP inhibition studies, the competitive
OATP inhibitor BSP (at 1 µM) was added to the medium and
therefore was present throughout the 30 min uptake time. The
cells were then washed twice in PBS, lysed using RIPA buffer, and
the intracellular 3H radioactivity measured by liquid scintillation
spectrometry. Cell protein content was also determined with a
BCA assay. Results are expressed as E1S uptake pmol/mg protein.
Immunoblotting
Protein concentration was determined from cell lysates using the
BCA assay, and 15 µg samples were separated by electrophoresis
under reducing conditions on 4–12% Bis-Tris 10% SDS-PAGE
gels (Invitrogen, Paisley, UK) before being transferred to PVDF
membranes. Membranes were immunoblotted with either ERα
(1:1000), ERβ (1:1000), GPER (1:800) (all from Santa Cruz,
UK), or β-actin (1:50,000) (Sigma-Aldrich, UK) monoclonal
antibodies in incubation buffer containing 0.1% milk (Marvel;
Premier Brands UK Ltd, Lincolnshire, UK) in TBST. For
full details of antibodies and conditions used see Table 1.
Bound antibody was detected with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibodies and
chemiluminescence detection.
siRNA Transfection
Twenty four hours after seeding HCT116 cultures were
transfected with OATP-specific and control siRNA (Thermo
Fisher Scientific, UK) by lipofectamine-2000 (Invitrogen) using
standard protocols. 72 h post-transfection, E1S uptake studies
were performed over 30 min and total E1S uptake calculated.
RESULTS
STS Activity in Intact and Lysed CRC Cell
Lines
The panel of four CRC cell lines, plus the positive control JEG3,
were investigated and demonstrate a wide range of STS activity
(Figures 2A,B). In intact (not lysed) cells, Caco2 exhibited the
highest STS activity (65.47 ± 28.51 pmol/mg/h), with HCT116
cells having the lowest activity (1.65 ± 0.14 pmol/mg/h). STS
activity could be almost completely inhibited in intact cells using
1 µM of the specific STS inhibitor STX64 (Figure 2A).
When lysed, the intracellular STS activity was much greater
in all cell lines examined compared to their intact state
(Figure 2B). STS activity was again greatest in the Caco2 cell
lines (452.90 ± 56.34 pmol/mg/h) with HCT116 cell showing
the lowest STS activity (11.87 ± 6.41 pmol/mg/h). These results
demonstrate that E1S uptake kinetics most likely dictate the
ability of CRC to hydrolyze E1. Therefore, as E1S is transported
through the cell membrane by OATPs the expression of these
transporters was next determined.
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TABLE 1 | Information regarding antibodies and conditions used for immunoblotting.
Antibody Manufacturer, Cat. #, Lot # Peptide/protein target Species raised,
monoclonal/polyclonal
Dilution used Positive control
ERα Santa Cruz, sc-130072, C2910 aa 301–595 Mouse, monoclonal 1:1000, 1% milk MCF-7
ERβ Abcam, ab288, GR79420-5 aa 1–153 Mouse, monoclonal 1:1000, 1% milk MCF-7
GPER Santa Cruz, sc-48525-R, F2414 N-terminus Rabbit, Polyclonal 1:800, 5% milk MCF-7
β-actin Sigma, A228 slightly modified β-cytoplasmic
actin N-terminal peptide
Mouse, Monoclonal 1:50,000
FIGURE 2 | (A) Steroid sulfatase activity (E1S conversion in pmol/mg/h) and inhibition by STX64 (1 µM) in intact CRC cell lines. (B) STS activity and inhibition by
STX64 (1 µM) in CRC cell lysate. JEG3 cells were used as a positive control in all experiments. Data represents mean ± SD. n = 3 independent experiments.
FIGURE 3 | Organic anion transporter polypeptide mRNA expression in
Colo205, Caco2, HCT116, and HT-29 cells. OATP4A1 expression was the
highest in all cell lines. Data represents mean ± SD. n = 3 independent
experiments.
OATP Expression and E1S Uptake in CRC
Cell Lines
The mRNA expression of OATPs known to transport E1S across
the plasma membrane was determined in the panel of CRC cell
lines (Figure 3). Of the six OATPs examined only OATP4A1
was present in all four cell lines. OATP2B1 expression was
also notably high in Caco2 cells. The HT29 cells expressed five
of the six OATPs determined (OATP1B3 was not present in
HT29 cells), with the Caco2 cells expressing four (OATP1A1,
OATP1B3, OATP2B1, OATP4A1) out of six. Our results are
roughly consistent with the expression patterns obtained from
the CellMiner database1, as shown by average transcript log2
intensities (see Table 2).
When the ability of CRC cells to transport E1S into the
cells was determined, Colo205 demonstrated the quickest
uptake rate, with HCT116 cells having the slowest uptake
(Figure 4A). Inhibition of OATP transport with the non-specific
OATP inhibitor BSP significantly reduced E1S uptake in
all four cell lines (Figures 4B–E). Caco2 cells had the
most rapid with HCT116 cells exhibited the slowest E1S
transport. E1S uptake after 30 min demonstrated that Colo205
(89.41 ± 16.80 pmol/mg) and Caco2 (61.78 ± 10.80 pmol/mg)
cells exhibited the most intracellular E1S transport, with HCT116
(16.73 ± 6.80 pmol/mg) and HT29 (34.59 ± 5.63 pmol/mg)
cells showing lower E1S transport (Figure 4F). BSP
1https://discover.nci.nih.gov/cellminer/
TABLE 2 | Average transcript log2 intensities determined from the National
Cancer Institute (NCI) CellMiner database (https://discover.nci.nih.gov/
cellminer/).
1A2 1B1 1B3 2B1 3A1 4A1
Colo205 3.24 3.22 5.50 7.29 4.76 8.38
HCT116 2.96 3.23 5.75 5.34 4.61 8.19
HT29 2.84 2.89 4.92 5.39 6.54 8.04
Average log2 determined from mRNA various probes/probe sets.
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FIGURE 4 | Estrone sulfate transport in Colo205, Caco2, HCT116 and HT-29 cells. (A) Comparison of the different uptake kinetics of E1S over 30 min in four
CRC cell lines. (B) Inhibition of Colo205 E1S transport by BSP (1 mM). (C) Inhibition of Caco2 E1S transport by BSP. (D) Inhibition of HCT116 E1S transport by BSP.
(E) Inhibition of HT-29 E1S transport by BSP. (F) Total E1S uptake over 30 min by four CRC cell lines and the total inhibition caused by BSP. Data represents
mean ± SD. n = 3 independent experiments. ∗∗∗p < 0.001 compared to control.
significantly (p < 0.001) inhibited E1S transport in all four
cell lines.
To examine if OATP inhibition by BSP reduces E1S
intracellular substrate availability to STS, we examined the effect
of BSP on STS activity in intact cells and cell lysates. We selected
Caco2 and HCT116 cells as representative of CRC cells with high
and low STS activity, respectively. In intact cells, treatment with
BPS (1 µM) non-significantly reduced STS activity in Caco2 cells
but had no effect on HCT116 STS activity (Figure 5A). When
BPS (1 µM) was tested in cell lysates it had no effect on STS
activity in both Caco2 and HCT116 cells, suggesting it does not
directly inhibit the STS enzyme (Figure 5B). These results imply
that OATP transport into cells plays a rate-limiting step on E1S
STS hydrolysis. The discrepancy between Caco2 and HCT116
cells in response to BSP most likely represents the difference
between the STS activity in the cell lines. When STS activity is
high (Caco2), limiting E1S OATP transport limits intracellular
E1S availability thus reducing E1 hydrolysis. When STS activity
is low (HCT116), limiting E1S OATP transport does not directly
translate to decreased hydrolysis as there is less STS activity, and
thus limiting substrate availability via OATP inhibition and where
enzyme activity is already low does not translate to reduced E1S
hydrolysis.
As OATP2B1 and OATP4A1 were expressed at the highest
concentrations compared to the other OATPs, we next performed
siRNA knockdown of these two transporters in HCT116 cells to
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FIGURE 5 | Bromsulfthalein has limited effect on STS activity Caco2 and HCT116 cells. (A) In intact cells, STS activity is non-significantly reduced by
BSP (1 µM) in Caco2 cells and has no effect on HCT116 cells. (B) In cell lysates, BSP (1 µM) has no effect on STS activity in Caco2 or HCT116 lysates. Data
represents mean ± SD. n = 3 independent experiments.
FIGURE 6 | OATP4A1 knockdown in HCT116 cells blocks E1S transport. (A) siRNA knockdown of OATP2B1 and OATP4A1 reduced transporter expression
by over 95%. (B) In HCT116 cells OATP2B1 knockdown has no effect on E1S transport, however OATP4A1 knockdown inhibited E1S transport by 52.4%. Data
represents mean ± SD. n = 3 independent experiments. ∗∗p < 0.01 compared to control.
determine their importance on E1S uptake. We used HCT116
cells as they had high OATP2B1 and OATP4A1 expression
without high expression of any other OATPs. Furthermore,
HCT116 cells are readily transfected by lipofectamine for siRNA
delivery. For both OATPs siRNA gave < 95% knockdown
as measured by qRT-PCR (Figure 6A). OATP2B1 knockdown
did not significantly affect E1S uptake (Figure 6B), however
OATP4A1 knockdown significantly reduced E1S uptake from
21.02 ± 3.12 to 8.93 ± 2.07 pmol/mg/h (p < 0.01), suggesting
this transporter may play a key role in E1S transport in CRC.
STS Activity is Regulated by E2
Availability and GPER Action in CRC
As steroid metabolism and estrogen action in the colon is poorly
defined we next speculated whether estrogens may influence
steroid sulfatase activity, as it has been reported to do in other
malignancies (Zaichuk et al., 2007). Thus we next examined
how E2 starvation and subsequent E2 supplementation effects
STS activity. HT29 cell treated with sFBS medium (i.e., estrogen
starvation) demonstrated a trend toward reduction in STS
activity, with this effect reversed when supplemented with E2
(Figure 7A). In HCT116 cells, 24 h of E2 (100 nM) treatment
significantly (p < 0.01) induced STS activity compared to sFBS
controls (Figure 7B).
We next attempted to inhibit this E2-induced increase in
STS activity by treating HCT116 with Tamoxifen or fulvestrant
co-administered with E2. Surprisingly, both Tamoxifen and
fulvestrant significantly increased STS activity in HCT116 cells
(Figure 7C) and neither compound had any effect on E2-induced
STS activity. Tamoxifen (at 10 nM) increased STS activity to
6.43 ± 0.95 pmol/mg/h and fulvestrant (1 µM) increase activity
to 7.84± 1.36 pmol/mg/h compared to 2.43± 0.31 pmol/mg/h.
Examination of the CRC cell lines ER status demonstrated that
ERα protein expression was present in Caco2 cells, and lowly
expressed in Colo205 cells. HCT116 and HT29 cells did not
express ERα (Figure 7D). None of the cell lines expressed ERβ
(Figure 7D). We also assessed the GPER status in our CRC cell
lines. HCT116 and HT29 cells expressed GPER (Figure 7E), as
did Caco2 and Colo205 (data not shown). Unedited immunoblots
are shown in Supplementary Figure 1. As both Tamoxifen and
fulvastrant have been shown to be GPER agonist (Prossnitz and
Barton, 2014) we next examined whether the increased STS
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FIGURE 7 | Steroid sulfatase activity is regulated by estrogen availability in CRC cell lines. (A) E2 (100 nM) does not increase STS activity in HT29. (B) E2
(100 nM) significantly increase STS activity in HCT116 cells. (C) 24 h treatment of Tamoxifen (10 nM) and fulvestrant (1 mM) increases STS activity in HCT116 cells.
(D) Colo205 and Caco2 cells express ERα, but not ERβ. HCT116 and HT29 cells do not express ERα or ERβ. The +ive control is MCF-7 protein. (E) GPER is
expressed in HCT116 and HT29 cells. Data represents mean ± SD. n = 3 independent experiments. ∗p < 0.05, ∗∗p < 0.01 compared to sFBS control.
activity induced by these compounds could be inhibited by G15,
a specific GPER antagonist (Dennis et al., 2009). In HCT116
cells, G15 (1 µM) significantly inhibited the increase of STS
activity induced by 24 h treatment with E2 (100 nM), the GPER
agonist G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 µM)
(Figure 8). This suggests a potential novel positive estrogen
metabolism feedback loop through GPER stimulation is present
in CRC.
DISCUSSION
Hormone replacement therapy, usually a combination of equine
E1S and progestins, may play a dual role in the incidence and
progression of CRC. Initially protective against the development
of CRC (Chlebowski et al., 2004), once the malignancy is
formed CRC may be estrogen responsive (Foster, 2013). Thus,
defining how CRC transports and metabolizes estrogens, and
the ER status of CRC, may define how this tissue responds
to HRT. Here we demonstrate that CRC cell lines possess
STS activity (see Figure 2) and are able to transport E1S (see
Figure 4), most likely through OATP4A1 (see Figure 6), into
cells. Furthermore, we show that STS activity is elevated by local
E2 concentrations (see Figure 7) via GPER action. Finally we
show that tamoxifen and fulvestrant, both GPER agonists, also
elevate STS activity (see Figure 8) indicating that its use in
breast cancer patients may have unwanted consequences in the
colon.
Elevated STS expression has been demonstrated in breast
(Pasqualini et al., 1996), prostate (Nakamura et al., 2006)
endometrial (Lepine et al., 2010), and epithelial ovarian cancer
(Ren et al., 2015). We demonstrate here for the first time that
STS activity is present in both intact and lysed CRC cells,
and this activity could be inhibited with STX64 (Figure 2).
Although the role of STS activity and estrogens in CRC is not yet
defined, our results, combined with evidence showing increased
STS expression as a poor prognostic indicator in CRC patients
(Sato et al., 2009), suggests STX64 as a potential therapeutic
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FIGURE 8 | Stimulation of GPER increases STS activity in HCT116
cells. E2 (100 nM), G1 (100 nM), Tamoxifen (10 nM), and fulvestrant (1 mM)
induce increased STS activity in HCT116 cells. These effects are inhibited by
the addition of the GPER antagonist G15 (1 mM). Data represents
mean ± SD. n = 3 independent experiments. ∗p < 0.05, ∗∗p < 0.01.
option for this disease. Indeed, STX64 has shown significant
promise in hormone-dependent breast cancer patients (Stanway
et al., 2006, 2007) with limited adverse events (Stanway et al.,
2006). Further Phase II trials of STX64 are currently ongoing in
patients with hormone-dependent breast cancer.
Cell protein (from cell lysates) exhibited significantly greater
STS activity compared to intact cells suggesting E1S cell
membrane transport as the limiting factor in estrogen hydrolysis.
Thus, OATP expression patterns in CRC may be a key
regulator of E1S transport and subsequent estrogen action. Our
results demonstrate OATP4A1, followed by OATP2B1, as the
most abundantly expressed E1S transporters in CRC cell lines
(Figure 3). OATP4A1 is up-regulated and hypomethylated in
CRC compared to normal colon tissue (Rawluszko-Wieczorek
et al., 2015), suggesting its importance in disease progression, and
implying that E1S uptake through this transporter may influence
tumor proliferation. Furthermore, OATP3A1 is down-regulated
in CRC (Rawluszko-Wieczorek et al., 2015), and reflected in our
results as low expression of this transporter is evident in all
four cell lines. OATP1B3 correlates to the Gleason score as a
marker of CRC dedifferentiation: higher OATP1B3 expression
in the colon is associated with earlier tumor stage and improved
tumor differentiation (Pressler et al., 2011). We demonstrate low
OATP1B3 expression in our cell lines, supporting a role for this
transporter in early tumor stage as all four cell lines examined
were derived from latter-stage tumors.
Once transported, E1S requires hydrolysis to form E1, and
subsequently E2 via 17β-hydroxysteroid dehydrogenase activity.
However, controversy surrounds how estrogens act in CRC.
Evidence suggests ERα is either lowly expressed (Cavallini
et al., 2002) or not present (Witte et al., 2001), and ERβ is
down-regulated during CRC development from colon adenomas
(Konstantinopoulos et al., 2003). Thus, we determined ER status
in four CRC cell lines, showing that Caco2 and Colo205 cells
have some ERα immunoreactivity (Figure 7). None of the cell
lines expressed ERβ. As they did not express either ERα or ERβ,
we selected HCT116 and HT29 cells and determined that they
expressed GPER. As ERα and ERβ are not present in CRC, this
suggests that estrogens may primarily act through GPER in CRC.
Indeed, estrogen binding to GPER increases colonic transit time
(Li et al., 2016) and is associated with pain severity in irritable
bowel disease (Qin et al., 2014). However, this is the first report
of GPER stimulation having a functional molecular consequence
in STS activity.
Intriguingly, E2 and G1, a specific GPER agonist, increased
STS activity in HCT116 cell lines (Figure 7), suggesting a
potential novel positive estrogen feedback loop is present
within CRC. In theory, greater STS activity should result in
increased local E1 and E2 synthesis. Little is known about
the regulation of STS activity. STS can undergo various
post-translational modifications resulting in greater activity
(Stengel et al., 2008), and this effect may be NF-κB regulated
(Jiang et al., 2016). However, there are no other reports that
estrogen availability impacts STS activity. In breast cancer,
GPER stimulation by tamoxifen does elevate the expression
of aromatase (Catalano et al., 2014), the enzyme involved
in estrogen synthesis from androgen pre-cursors. It is with
some interest then to see that tamoxifen also increased STS
activity in HCT116 cell lines. As a selective ER modulator,
tamoxifen is a first line therapy against hormone-dependent
breast cancer. However, it has recently been shown that
tamoxifen may act as a GPER agonist in tamoxifen-resistant
tumors (Mo et al., 2013). Thus, tamoxifen-induced increase of
STS activity, and therefore increasing local estrogen availability,
in CRC and potentially other malignancies may represent a
novel GPER-stimulated pathway regulating STS action. It will
be of importance to further examine whether tamoxifen and
fulvestrant induce STS activity via GPER stimulation, as this
may represent a novel route for tamoxifen and fulvestrant
resistance.
CONCLUSION
We have demonstrated here that CRC cell lines can transport
E1S and have sufficient STS activity to liberate E1. STS
activity is possibly regulated by local estrogen availability
through GPER stimulation, and this represents a novel positive
estrogen feedback loop within CRC. These results have direct
consequences for HRT therapy, suggesting that HRT may
increase STS activity in the colon leading to potentially undesired
effects through GPER action.
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